BEAM logo

BEAM
Beam Therapeutics Inc

6,498
Mkt Cap
$3.39B
Volume
1.8M
52W High
$36.44
52W Low
$15.60
PE Ratio
-47.93
BEAM Fundamentals
Price
$32.93
Prev Close
$32.80
Open
$32.75
50D MA
$28.32
Beta
1.89
Avg. Volume
2.14M
EPS (Annual)
-$0.8088
P/B
2.91
Rev/Employee
$273,469.67
$1,650.58
Loading...
Loading...
News
all
press releases
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum PR Newswire NEW YORK, May 28, 2026 USA News Group News CommentaryIssued on behalf ofAva Bio, Inc.As...
PR Newswire
News Placeholder
More News
News Placeholder
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Key PointsCRISPR Therapeutics has an approved product and several gene editing medicines in development...
Nasdaq News: Markets
News Placeholder
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Zacks
News Placeholder
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Key PointsInitiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price...
Nasdaq News: Markets
News Placeholder
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026 The...
PR Newswire
News Placeholder
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
Zacks
News Placeholder
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -4.60% and +52.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Beam Therapeutics Inc. Q1 Loss Declines
(RTTNews) - Beam Therapeutics Inc. (BEAM) reported Loss for first quarter of -$94.32 million...
Nasdaq News: Markets
News Placeholder
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and...
MarketBeat
News Placeholder
Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday
Beam Therapeutics (NASDAQ:BEAM) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available